Sai Parenterals

Sai Parenterals

CLOSED

IPO Date: 24 Mar - 27 Mar 2026

Listing Date: 2 Apr 2026

Price Range

Rs.372 - Rs.392

Issue Size

409 Cr

Min Investment

14,136

Lot Size

38 Shares

Schedule of Sai Parenterals

Issue open date

24 Mar 2026

Issue close date

27 Mar 2026

UPI mandate deadline

27 Mar 2026 (5 PM)

Allotment finalization

30 Mar 2026

Share credit

1 Apr 2026

Listing date

2 Apr 2026

Mandate end date

12 Apr 2026

Issue size

Funds Raised in the IPOAmount
Overall409 Cr
Fresh Issue285 Cr
Offer for Sale123.79 Cr

Allotment DetailsNew

Allotment TimelineDetails
Allotment Date30 Mar 2026
Allotment Link{Link}

Grey Market PremiumNew

Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.

DateIpo PriceGMPEstimated Listing Price
29 Mar 20263920392 (0%)
28 Mar 20263920392 (0%)
26 Mar 20263920392 (0%)
25 Mar 20263920392 (0%)
23 Mar 20263920392 (0%)
22 Mar 20263920392 (0%)
21 Mar 20263920392 (0%)
20 Mar 20263920392 (0%)
19 Mar 20263920392 (0%)
18 Mar 20263920392 (0%)
17 Mar 20263920392 (0%)

Performance Sai Parenterals

Issue PriceListing GainCurrent Market PriceP/L
Rs.372 - Rs.392............

About Sai Parenterals

Sai Parenteral’s Limited is a pharmaceutical formulations company engaged in the research, development, and manufacturing of pharmaceutical products. The company operates in two main segments: branded generic formulations and contract development and manufacturing organisation (CDMO) services for domestic and international markets. Its product portfolio covers multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins and supplements, analgesics, and dermatology. The company manufactures products in several dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenterals supplies its branded generic formulations to customers, including government agencies, pharmaceutical companies, hospitals, and distributors in India, and also exports products to markets such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company operates five manufacturing facilities in India, four of which are located in Hyderabad, Telangana, while another facility owned by its subsidiary Revat Laboratories is located in Ongole, Andhra Pradesh. These facilities manufacture pharmaceutical formulations in compliance with applicable regulatory standards.

Founded in2001
Managing directorMr Anil Kumar Karusala
Parent organization

Financial Overview

Strengths

  • Diversified pharma portfolio across branded generics and CDMO services
  • Strong capabilities in sterile injectable manufacturing
  • Presence across multiple therapeutic areas and dosage forms
  • Promoter-led management with a long operating track record
  • Multiple manufacturing facilities supported by in-house R&D

Risks

  • High revenue dependence on injectable formulations
  • Manufacturing facilities are concentrated in limited geographies
  • Exposure to stringent regulatory inspections and compliance risks
  • Dependence on third-party suppliers for key raw materials
  • Customer concentration may affect revenue stability

Subscription Figures

CategorySubscription (No. of times)
Qualified Institutional Buyers (QIBs)1.71
Non-Institutional Investors (NIIs)2.36
Retail Individual Investors (RIIs)0.12
EmployeeN/A
Total1.05